Alexion, AstraZeneca’s Rare Disease group, plans to expand its presence in New Haven with space at the new bioscience tower currently under construction at 101 College Street.
The company is headquartered in Boston, but has a New Haven presence, with roughly 500 employees working at its research facility at the existing tower next door, at 100 College Street.
Alexion indicated it expects to occupy the new space by the end of 2023. The expansion is expected to grow the company’s research capabilities, and will double its lab floor space.